Safety and Pharmacokinetics of Famciclovir Single 1500 mg Dose in Adolescents With Recurrent Herpes Labialis

Last updated: June 3, 2021
Sponsor: Novartis Pharmaceuticals
Overall Status: Completed

Phase

2/3

Condition

Genital Herpes

Herpes Simplex Infections

Cold Sores (Herpes Labialis Infections)

Treatment

N/A

Clinical Study ID

NCT00878072
CFAM810B2305
  • Ages 12-18
  • All Genders

Study Summary

This study will assess the safety, tolerability of a single 1500 mg dose of famciclovir in 50 adolescents with recurrent herpes labialis. Eight of the 50 adolescents will also participate in the pharmacokinetics (PK) assessment of famciclovir single 1500 mg dose

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Outpatient males or females 12 to <18 years of age
  • General good health with a documented history typical for recurrent herpes labialis
  • Prodromal symptoms or active lesions suggestive of a recurrent episode of herpeslabialis (i.e. having had cold sores in the past) , with onset not exceeding 24 hoursuntil the time of study drug administration
  • Adolescents participating in Pharmacokinetics (PK) part of the study may beenrolled without an active herpes labialis recurrence or with onset ofsigns/symptoms of a recurrent herpes labialis episode longer than 24 hours beforestudy drug administration, All adolescents participating in the pharmacokineticsassessments must fast for at least 8 hours prior to Visit 1 and be willing tofast for an additional 2 hours after study drug administration

Exclusion

Exclusion Criteria:

  • Use of other investigational drugs within 30 days of enrollment
  • History of hypersensitivity to famciclovir or penciclovir
  • Inability to swallow tablets
  • Body weight less than 40 Killograms (kg)
  • History of malabsorption, unless a condition like celiac disease is stable and wellcontrolled, previous gastrointestinal surgery or radiation therapy that could affectdrug absorption or metabolism, or any condition that could interfere with drugabsorption, distribution, metabolism, or excretion
  • Known renal insufficiency (calculated creatinine clearance <60 [Milliliters/Minutes]mL/min)
  • Known severe hepatic impairment (Child-Pugh Class C)
  • Significant skin disease such as atopic dermatitis or eczema that would interfere withassessment of oral/labial lesions
  • Known to be immunocompromised or are receiving systemic or using topicalimmunosuppressive agents (including corticosteroids, tacrolimus and picrolimus) within 30 days of enrollment
  • Concomitant use of probenecid
  • Pregnant or nursing (lactating) females
  • Females of child-bearing potential, UNLESS they are using two birth control methods.The two methods can be a double barrier method or a barrier method plus a hormonalmethod.

Study Design

Total Participants: 53
Study Start date:
March 25, 2009
Estimated Completion Date:
June 02, 2010

Study Description

Uncontrolled study

Connect with a study center

  • Women's Health Care at Frost Street

    San Diego, California
    United States

    Site Not Available

  • Children's Memorial Hospital

    Chicago, Illinois 60614
    United States

    Site Not Available

  • Medisphere Medical Research Center, LLC

    Evansville, Indiana 47714
    United States

    Site Not Available

  • Clayton Medical Research

    Saint Louis, Missouri 63117
    United States

    Site Not Available

  • Clayton Medical Research

    St. Louis, Missouri 63117
    United States

    Site Not Available

  • Rochester Clinical Research, Inc.

    Rochester, New York
    United States

    Site Not Available

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio 45229
    United States

    Site Not Available

  • University Hospitals Case Medical Center

    Cleveland, Ohio 44106
    United States

    Site Not Available

  • Westover Heights Clinic

    Portland, Oregon 97210
    United States

    Site Not Available

  • Primary Physicians Research, Inc

    Pittsburgh, Pennsylvania
    United States

    Site Not Available

  • Texas Children's Hospital

    Houston, Texas 77030
    United States

    Site Not Available

  • R/D Clinical Research

    Lake Jackson, Texas 77566
    United States

    Site Not Available

  • R/D Clinical Research, Inc

    Lake Jackson, Texas 77566
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.